Aclacinomycin A | 阿克拉霉素A | Aclarubicin | Topoisomerase Inhibitor

首页 / / / / Aclacinomycin A

阿克拉霉素 /Aclacinomycin A {[allProObj[0].p_purity_real_show]}

货号：A682704 同义名： 阿克拉霉素A / Aclarubicin;NSC 208734

Aclarubicin is an oligosaccharide anthracycline antineoplastic antibiotic isolated from the bacterium Streptomyces galilaeus.

Aclacinomycin A 化学结构
CAS号：57576-44-0

Aclacinomycin A 3D分子结构
CAS号：57576-44-0

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Aclacinomycin A 纯度/质量文件产品仅供科研

货号：A682704 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Nat. Biomed. Eng., 2024, 8, 1412-1424. Ambeed. [ A538667 , A631746 ]; • JMC, 2024. Ambeed. [ A833302 , A475501 , A341986 , A356070 ]; • BMC Cancer, 2024, 24(1): 1415. Ambeed. [ A809692 , A209020 ]; • J. Am. Soc. Mass Spectrom., 2024, 35(12): 3192-3202. Ambeed. [ A166127 , A902473 , A753371 , A961334 , A292945 , A230770 , A300620 , A1114580 , A1159765 , A206238 ]; • PloS One, 2024, 19(11): e0308060. Ambeed. [ A302917 ]; 更多 >

DNA 亚型比较
拓扑异构酶亚型比较
蛋白酶体亚型比较

产品名称	DNA synthesis ↓ ↑	helicase ↓ ↑	RdRp ↓ ↑	ribonucleotide reductase ↓ ↑	tRNA synthetase ↓ ↑	YB-1 ↓ ↑	其他靶点	纯度
Fexinidazole	✔							98%
Daptomycin	✔							98%
Blasticidin S·HCl	✔							98%
Metronidazole	✔							98%
Daunorubicin HCl	+++ DNA synthesis, Ki: 20 nM							98%
Triglycidyl isocyanurate	✔						p53	98+%
Nedaplatin	✔							99%+
Bendamustine	✔							98+%
Trifluridine	✔							98%
Robinetin	✔							99%+
Carboplatin	✔							99%
Cidofovir	✔							99%
Cisplatin	✔							99%
Cytarabine	++++ DNA synthesis, IC50: 16 nM							98%
Acelarin	++++ DNA synthesis, EC50: 0.2 nM							99%+
Oxaliplatin	✔							98%
YK-4-279		✔						99%+
ML216		+ BLM^full-length, IC50: 2.98 μM BLM^636-1298, IC50: 0.97 μM						99%+
RK-33		✔						98%
Brr2-IN-3		✔						99%+
Phen-DC3 Trifluoromethanesulfonate		✔						98%
Favipiravir			✔					97%
Suramin sodium salt			++ RdRp, IC50: 0.26 μM					99%+
Clofarabine				++ Ribonucleotide reductase, IC50: 65 nM				97%
Didox				✔				98%
(E)-3-AP				✔				97%
Halofuginone					+++ prolyl-tRNA synthetase, Ki: 18.3nM			99%+
BC-LI-0186					+++ Leucyl-tRNA synthetase, Kd: 42.1 nM Leucyl-tRNA synthetase, IC50: 46.11 nM			98%
SU056						+ YB-1, IC50: 1.73 μM		98%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

产品名称	Topo I ↓ ↑	Topo II ↓ ↑	Topo IV ↓ ↑	Topoisomerase ↓ ↑	其他靶点	纯度
Ellagic acid	✔					98%
β-Lapachone	✔					99%+
(s)-10-hydroxycamptothecin	✔					98+%
Camptothecin	++ Topo I, IC50: 0.68 μM					98%
Betulinic acid	++ Eukaryotic topoisomerase I, IC50: 5 μM					98%
Topotecan	++++ Topo I (DU-145 Luc cells), IC50: 2 nM Topo I (MCF-7 Luc cells), IC50: 13 nM					98%
Irinotecan HCl Trihydrate	✔					98%
SN-38	✔					98%
Levofloxacin hydrate		✔				98%
Dexrazoxane		✔				99%+
Ofloxacin		✔				98+%
Enoxacin		✔				99%+
Flumequine		+ Topo II, IC50: 15 μM				98%
Levofloxacin		✔				97%
Etoposide		✔				98%
Pefloxacin mesylate dihydrate		✔				99+%
Marbofloxacin		✔				98+%
Voreloxin HCl		✔				98%
Mitoxantrone dihydrochloride		✔			PKC	98%
Nalidixic acid		✔				98%
Doxorubicin		✔				98%
Novobiocin sodium		✔				95%
Amonafide		✔				99%+
Pirarubicin		✔				98%+
Idarubicin HCl		+++ Topo II (MCF-7 cells), IC50: 3.3 ng/mL				99%+
Genistein		✔			EGFR	98%
Teniposide		✔				98%
Moxifloxacin		✔				98%
Ciprofloxacin			✔			98%
Clinafloxacin			✔			97%
Gatifloxacin				✔		98%
Daunorubicin HCl				+++ DNA synthesis, Ki: 20 nM		98%
Epirubicin HCl				✔		99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

产品名称	20S proteasome ↓ ↑	Proteasome ↓ ↑	纯度
Ixazomib	++++ 20S proteasome, Ki: 0.93 nM 20S proteasome, IC50: 3.4 nM		99%+
Delanzomib	+++ Chymotrypsin-like proteasome, IC50: 3.8 nM		98%
Celastrol	+ 20S proteasome, IC50: 2.5 μM		98%
MLN9708	+++ 20S proteasome, Ki: 0.93 nM 20S proteasome, IC50: 3.4 nM		99%
Bortezomib	++++ 20S proteasome, Ki: 0.6 nM		98%
Oprozomib	++ 20S proteasome β5, IC50: 36 nM 20S proteasome LMP7, IC50: 82 nM		99%+
Epoxomicin	✔		99%
PI-1840	++ Chymotrypsin-like proteasome, IC50: 27 nM		98%
VR23		+++ Trypsin-like proteasomes, IC50: 1 nM Chymotrypsin-like proteasomes, IC50: 3 μM	98%
Carfilzomib		++ Proteasome, IC50: 5 nM	98%
(R)-MG-132		+ Proteasome, IC50: 100 nM	98%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Aclacinomycin A 生物活性

描述

Aclarubicin is an oligosaccharide anthracycline antineoplastic antibiotic isolated from the bacterium Streptomyces galilaeus. Aclarubicin intercalates into DNA and interacts with topoisomerases I and II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. Aclarubicin is antagonistic to other agents that inhibit topoisomerase II, such as etoposide, teniposide and amsacrine.

Aclacinomycin A 临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT03026842	Acute Myeloid Leukemia	Phase 4	Active, not recruiting	October 2024	China, Jilin ... 展开 >> First Hospital of Jilin University Changchun, Jilin, China, 130021 收起 <<
NCT02432911	Acute Myeloid Leukemia	Not Applicable	Recruiting	May 2021	China, Tianjin ... 展开 >> Treatment and Diagnosis Center of Leukemia Recruiting Tianjin, Tianjin, China, 300020 Contact: Jianxiang Wang, MD +862223909120 wangjx@medmail.com.cn Contact: Chunlin Zhou, MD +8613820429085 zcl7317@sina.com 收起 <<
NCT03560908	Relapsed AML ... 展开 >>T(8;21) C-KIT Mutation 收起 <<	Phase 1	Recruiting	December 31, 2020	China, Tianjin ... 展开 >> HBDH Recruiting Tianjin, Tianjin, China, 300020 Contact: Hui Wei 收起 <<

Aclacinomycin A 参考文献

[1]Cao J, Feng H, et al. Homoharringtonine combined with aclarubicin and cytarabine synergistically induces apoptosis in t(8;21) leukemia cells and triggers caspase-3-mediated cleavage of the AML1-ETO oncoprotein. Cancer Med. 2016 Nov;5(11):3205-3213.

[2]Traganos F, Staiano-Coico L, et al. Effects of aclacinomycin on cell survival and cell cycle progression of cultured mammalian cells. Cancer Res. 1981 Jul;41(7):2728-37.

Aclacinomycin A 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

1.23mL

0.25mL

0.12mL

6.16mL

1.23mL

0.62mL

12.32mL

2.46mL

1.23mL

Aclacinomycin A 技术信息

CAS号	57576-44-0
分子式	C₄₂H₅₃NO₁₅
分子量	811.87

别名	阿克拉霉素A ;Aclarubicin;NSC 208734;MA 144-A1;Antibiotic MA 144A;Aclucinomycin A;Aclarubicine;Aclacur
运输	蓝冰

存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Keep in dark place,Inert atmosphere,2-8°C

溶解度

DMSO: 50 mg/mL(61.59 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验配方

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT03026842	Acute Myeloid Leukemia	Phase 4	Active, not recruiting	October 2024	China, Jilin ... 展开 >> First Hospital of Jilin University Changchun, Jilin, China, 130021 收起 <<
NCT02432911	Acute Myeloid Leukemia	Not Applicable	Recruiting	May 2021	China, Tianjin ... 展开 >> Treatment and Diagnosis Center of Leukemia Recruiting Tianjin, Tianjin, China, 300020 Contact: Jianxiang Wang, MD +862223909120 wangjx@medmail.com.cn Contact: Chunlin Zhou, MD +8613820429085 zcl7317@sina.com 收起 <<
NCT03560908	Relapsed AML ... 展开 >>T(8;21) C-KIT Mutation 收起 <<	Phase 1	Recruiting	December 31, 2020	China, Tianjin ... 展开 >> HBDH Recruiting Tianjin, Tianjin, China, 300020 Contact: Hui Wei 收起 <<
NCT03045627	Acute Myeloid Leukemia	Phase 2	Recruiting	July 2020	China, Shandong ... 展开 >> Qilu hospital, Shandong University Recruiting Jinan, Shandong, China, 250012 Contact: Ming Hou houming@medmail.com.cn Principal Investigator: Ming Hou 收起 <<
NCT02886559	AML Relapse	Phase 1 Phase 2	Recruiting	June 2019	China ... 展开 >> China PLA General Hospital Recruiting Beijing, China, 100039 Contact: Li Yu, M.D Ph.D 010-66937644 chunhuiliyu@yahoo.com Principal Investigator: Li-Xin Yu 收起 <<
NCT03181815	Acute Myeloid Leukemia ... 展开 >> Relapse Leukemia 收起 <<	Phase 2	Recruiting	May 1, 2019	China, Guangdong ... 展开 >> Liang Wang Recruiting Guangzhou, Guangdong, China, 510060 Contact: Liang Wang, M.D. +862087342439 wangliang@sysucc.org.cn 收起 <<
NCT02723448	Vasculopathy, Retinal, With Ce... 展开 >>rebral Leukodystrophy Cerebroretinal Vasculopathy, Hereditary 收起 <<	Phase 1	Active, not recruiting	March 2019	United States, Missouri ... 展开 >> Washington University School of Medicine Saint Louis, Missouri, United States, 63110 收起 <<

阿克拉霉素 /Aclacinomycin A {[allProObj[0].p_purity_real_show]}

Aclacinomycin A 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Aclacinomycin A 质控信息

Aclacinomycin A 生物活性

Aclacinomycin A 临床研究

Aclacinomycin A 参考文献

Aclacinomycin A 实验方案

Aclacinomycin A 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

阿克拉霉素 /Aclacinomycin A {[allProObj[0].p_purity_real_show]}

Aclacinomycin A 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Aclacinomycin A 质控信息

Aclacinomycin A 生物活性

Aclacinomycin A 临床研究

Aclacinomycin A 参考文献

Aclacinomycin A 实验方案

Aclacinomycin A 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Aclacinomycin A 纯度/质量文件产品仅供科研